Results 1 to 10 of about 181,126 (162)

Trial watch: TLR3 agonists in cancer therapy

OncoImmunology, 2020
Toll-like receptor 3 (TLR3) is a pattern recognition receptor that senses exogenous (viral) as well as endogenous (mammalian) double-stranded RNA in endosomes. On activation, TLR3 initiates a signal transduction pathway that culminates with the secretion
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli   +4 more
doaj   +1 more source

Expression and clinical significance of PD-1, PD-L1 and tumor infiltrating lymphocytes in neuroblastoma

Zhongguo linchuang yanjiu
Objective To investigate the expression of programmed cell death protein 1(PD-1), programmed cell death 1 ligand 1 (PD-L1) and tumor infiltrates lymphocytes (TIL) density in neuroblastoma and the relationship between them and the clinicopathological ...
QIAO Jiahua*, HAO Ziqi, HUANG Ye, WEI Junni, LI Suhong
doaj   +1 more source

Diabetic ketoacidosis after treatment with pembrolizumab

Journal of Clinical and Translational Endocrinology Case Reports, 2017
Immune checkpoint inhibiting agents have been shown to precipitate type 1 diabetes. We report a case of acute severe diabetic ketoacidosis in a patient with no history of diabetes who developed ketoacidosis after starting anti-PD1 immunotherapy with ...
M. Hariz. F. Abdul Aziz, Isuru P. Fernando, Anjan Lenkanpally, Devaka J.S. Fernando   +3 more
doaj   +1 more source

RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. [PDF]

PLoS ONE, 2011
Programmed necrosis/necroptosis is an emerging form of cell death that plays important roles in mammalian development and the immune system. The pro-necrotic kinases in the receptor interacting protein (RIP) family are crucial mediators of programmed ...
YoungSik Cho, Thomas McQuade, Haibing Zhang, Jianke Zhang, Francis Ka-Ming Chan   +4 more
doaj   +1 more source

Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma

Chinese Journal of Lung Cancer, 2018
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors were landmarks in the treatment of non-small cell lung cancer (NSCLC ...
Xuefeng LENG, Jiandong MEI, Lunxu LIU
doaj   +1 more source

Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1 [PDF]

Infection and Immunity, 2011
ABSTRACTTrypanosoma cruziinfection causes intense myocarditis, leading to cardiomyopathy and severe cardiac dysfunction. Protective adaptive immunity depends on balanced signaling through a T cell receptor and coreceptors expressed on the T cell surface.
Fredy R S, Gutierrez, Flávia S, Mariano, Carlo J F, Oliveira, Wander R, Pavanelli, Paulo M M, Guedes, Grace K, Silva, Ana P, Campanelli, Cristiane M, Milanezi, Miyuki, Azuma, Tasuku, Honjo, Mauro M, Teixeira, Julio C S, Aliberti, João S, Silva   +12 more
openaire   +2 more sources

Inhibitory Immune Checkpoints beyond Programmed Cell Death Ligand 1 in Merkel Cell Carcinoma: Abundant Expression of TIGIT Independent of the Presence of Merkel Cell Polyoma Virus

Acta Dermato-Venereologica
Merkel cell carcinoma is a rare, aggressive skin cancer in which Merkel cell polyoma virus (MCPyV) is frequently pathogenically involved. After failure of anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy, therapeutic ...
Ferdinand Toberer, Julia K. Winkler, Leroy Atienza Fernandez, Lea Adams, Alexander Brobeil, Marcell Tóth, Alexander H. Enk, Jürgen C. Becker, Anke Lonsdorf   +8 more
doaj   +1 more source

Expression of PD-1/PD-L1 pathway molecules in human cardiac allograft according to acute cellular rejection status: insights from a Korean Heart Transplant Cohort [PDF]

Journal of Pathology and Translational Medicine
Background Acute cellular rejection (ACR) following heart transplantation (TPL) compromises graft function and survival. The programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) pathway represents an immune checkpoint that maintains peripheral immune ...
Jeemin Yim, Yoon Kyung Jeon, Doo Hyun Chung, Jaemoon Koh   +3 more
doaj   +1 more source

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung

Thoracic Cancer, 2022
Background A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery.
Yuan Feng, Wei Sun, Jie Zhang, Yang Wang, Jinfeng Chen, Xinying Liu, Liang Wang, Shaolei Li, Chao Lv, Fangliang Lu, Jianzhi Zhang, Yang Hong, Shanshan Xiao, Tao Wang, Raymond Jiao, Ziping Wang, Liping Qi, Nan Li, Yue Yang, Dongmei Lin, Jian Fang   +20 more
doaj   +1 more source

In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network [PDF]

Journal of Biological Chemistry, 2017
Programmed cell death-1 (PD-1) is an inhibitory receptor with an essential role in maintaining peripheral tolerance and is among the most promising immunotherapeutic targets for treating cancer, autoimmunity, and infectious diseases. A complete understanding of the consequences of PD-1 engagement by its ligands, PD-L1 and PD-L2, and of PD-L1 binding to
Li, Kaitao, Cheng, Xiaoxiao, Tilevik, Andreas, Davis, Simon J., Zhu, Cheng   +4 more
openaire   +3 more sources